bitop AG and Activaero collaborate on clinical study of inhalable Ectoin-solution
The present clinical study is a single-center dose-finding, safety and feasibility study involving patients with mild bronchial asthma in Germany. Ectoin® inhalation solution has already shown marked therapeutic efficacy in animal models of allergen induced asthma and the purpose of the study is to investigate the safety and tolerability of Ectoin® inhalation solution in the treatment of asthma.
According to the company, the AKITA²® inhalation system allows for homogeneous drug deposition of aerosolized Ectoine® within the periphery of the lungs in a consistent and reproducible manner. The system also has a smart card technology meaning that data on compliance and dosing can be recorded automatically for each patient.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.